Your browser doesn't support javascript.
loading
Corrigendum to 'Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxis' [Research and Practice in Thrombosis and Haemostasis, Volume 7, Issue 2, February 2023, 100077].
Pipe, Steven W; Trzaskoma, Ben; Minhas, Miranda; Lehle, Michaela; Ko, Richard H; Gao, Ling; Mahlangu, Johnny; Kempton, Christine L; Kessler, Craig M; Kruse-Jarres, Rebecca.
Afiliação
  • Pipe SW; Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor, Michigan, USA.
  • Trzaskoma B; US Medical Affairs, Genentech Inc, South San Francisco, California, USA.
  • Minhas M; US Medical Affairs, Genentech Inc, South San Francisco, California, USA.
  • Lehle M; Product Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Ko RH; US Medical Affairs, Genentech Inc, South San Francisco, California, USA.
  • Gao L; Analystat Corporation, Point Roberts, Washington, USA.
  • Mahlangu J; Department of Molecular Medicine and Haematology, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand and National Health Laboratory Service, Johannesburg, South Africa.
  • Kempton CL; Department of Hematology and Medical Oncology and Hemophilia of Georgia Center for Bleeding & Clotting Disorders of Emory, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Kessler CM; The Division of Coagulation, Georgetown University School of Medicine, Washington, DC, USA.
  • Kruse-Jarres R; Division of Hematology, University of Washington and Washington Center for Bleeding Disorders, Seattle, Washington, USA.
Res Pract Thromb Haemost ; 7(4): 100191, 2023 May.
Article em En | MEDLINE | ID: mdl-37538504
ABSTRACT
[This corrects the article DOI 10.1016/j.rpth.2023.100077.].

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article